Skip to main content
Skip to main content
News
Contact
About us
Executive Leadership Team
Board of Directors
Scientific Advisors
Our Pipeline
Zerlasiran
Divesiran
Our Technology
How RNAi Works
Intellectual Property
Scientific Publications
Partnering
Patients
High Lp(a)
Polycythemia Vera
Expanded Access Policy
Clinical Trials
A Platform for Progress: Our Clinical Studies
Investors
Press Releases
Events & Presentations
Share Information
Share Quote
Share Chart
Investment Calculator
Historical Lookup
Shareholder Information
Analyst Coverage & Key advisers
Financials
SEC Filings
Annual Reports
Quarterly Reports
Governance
Executive Leadership
Board of Directors
Governance Documents
AIM Delisting
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Careers
Site Search
Search query
About us
Executive Leadership Team
Board of Directors
Scientific Advisors
Our Pipeline
Zerlasiran
Divesiran
Our Technology
How RNAi Works
Intellectual Property
Scientific Publications
Partnering
Patients
High Lp(a)
Polycythemia Vera
Expanded Access Policy
Clinical Trials
A Platform for Progress: Our Clinical Studies
Investors
Press Releases
Events & Presentations
Share Information
Share Quote
Share Chart
Investment Calculator
Historical Lookup
Shareholder Information
Analyst Coverage & Key advisers
Financials
SEC Filings
Annual Reports
Quarterly Reports
Governance
Executive Leadership
Board of Directors
Governance Documents
AIM Delisting
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Careers
NASDAQ: SLN
Press Releases Details
Home
/
Investors
/
Press Releases
/
Press Releases Details
View all news
Divesiran, A Novel GalNAc Conjugated siRNA, Reduces Phlebotomies, Improves Iron Stores and Symptoms in Polycythemia Vera Patients in SANRECO Phase 1 Study
06/11/2026
Download
PDF Format (opens in new window)
PDF 660 KB
Multimedia Files:
View all news